| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 47.17 | 0.96 (+2.08%) | 32.51 - 47.34 | 5.2 million |
Market data as of 4:04PM 05/17/13. Quotes are delayed by at least 15 min.
| Open | 46.03 |
|---|---|
| Previous Close | 46.21 |
| Day's Range | 45.85 - 47.34 |
| Market Cap | 74.7B |
| Avg Volume (10 Day) | 5.0M |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | |
| Dividend Yield | 0.40 (3.39%) |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Neutral |
|---|---|
| Room to increase dividends? | Pass |
| Increased earnings over time? | Neutral |
| Borrows within reasonable limits? | Fail |
| Stock is undervalued? | Pass |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease
PR Newswire - Friday 05/17/2013 1:15 AM ET
AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
PR Newswire - Wednesday 05/15/2013 6:21 PM ET
AbbVie and Alvine to Collaborate on Investigational Oral Therapy for Celiac Disease
Business Wire - Tuesday 05/14/2013 9:25 AM ET
AbbVie and Alvine to Collaborate on Investigational Oral Therapy for Celiac Disease
PR Newswire - Tuesday 05/14/2013 9:15 AM ET
AbbVie to Present at Bank of America Merrill Lynch 2013 Health Care Conference
PR Newswire - Tuesday 05/07/2013 9:00 AM ET
AbbVie's Investigational HCV Regimen Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration
PR Newswire - Monday 05/06/2013 9:00 AM ET
AbbVie CF Scholarship Application Now Available for Exceptional Undergraduate and Graduate Students with Cystic Fibrosis
PR Newswire - Wednesday 05/01/2013 11:00 AM ET
AbbVie Reports First-Quarter 2013 Financial Results
PR Newswire - Friday 04/26/2013 7:51 AM ET
| ABBV | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 44.18% | |
| Net Income Growth (1yr) | 750.19% | |
| Total Debt/Equity | 5.09 | |
| LT Debt/Equity | 4.94 | |
| Earnings Yield | -- | |
| Price/Sales | 4.03 |
| Company | Last | Change |
|---|---|---|
| Bristol-Myers Squibb Co | 43.30 | +1.24% |
| Eli Lilly and Co | 55.90 | -0.07% |
| Merck & Co Inc | 45.99 | -0.82% |
| GlaxoSmithKline PLC | 52.22 | +0.21% |
| Zoetis Inc | 33.90 | +1.53% |
Data is delayed by at least 15 min.